{"id":"chloroquine-prophylaxis","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, abdominal pain)"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Pruritus"},{"rate":"5-10","effect":"Visual disturbances (blurred vision, accommodation difficulty)"},{"rate":"1-5","effect":"Retinopathy (with long-term use)"},{"rate":"<1","effect":"Cardiomyopathy (rare, with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL76","moleculeType":"Small molecule","molecularWeight":"319.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chloroquine is a quinoline antimalarial that concentrates in the acidic food vacuoles of malaria parasites, disrupting their ability to detoxify heme and leading to parasite death. Beyond antiparasitic effects, it also modulates immune function by raising intracellular pH, reducing inflammatory cytokine production, and inhibiting toll-like receptor signaling, making it useful for both infectious disease prevention and certain autoimmune conditions.","oneSentence":"Chloroquine inhibits parasitic growth and modulates immune responses by accumulating in acidic compartments and interfering with parasite metabolism and host inflammatory pathways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:11.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prophylaxis in endemic regions"},{"name":"Malaria treatment"},{"name":"Lupus erythematosus"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT04481633","phase":"NA","title":"Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2020-09-09","conditions":"COVID-19","enrollment":552},{"nctId":"NCT06575647","phase":"PHASE4","title":"Vivax Elimination With Tafenoquine (VET) Study","status":"COMPLETED","sponsor":"Shoklo Malaria Research Unit","startDate":"2025-02-19","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax","enrollment":1242},{"nctId":"NCT04344379","phase":"PHASE3","title":"Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-17","conditions":"SARS-CoV-2 Infection","enrollment":122},{"nctId":"NCT06083688","phase":"PHASE4","title":"Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-10-14","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":1000},{"nctId":"NCT04397328","phase":"PHASE3","title":"COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada","status":"WITHDRAWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-05-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT06666491","phase":"PHASE3","title":"An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Malaria, Vivax","enrollment":300},{"nctId":"NCT03032406","phase":"PHASE2","title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-01-23","conditions":"Breast Cancer Stage IIB","enrollment":53},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT02603146","phase":"PHASE2","title":"Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-27","conditions":"Healthy Participants, Rheumatoid Arthritis (RA) Prevention","enrollment":144},{"nctId":"NCT04335084","phase":"PHASE2","title":"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"ProgenaBiome","startDate":"2020-06-22","conditions":"COVID-19, Coronavirus Infection, Sars-CoV2","enrollment":254},{"nctId":"NCT04363827","phase":"PHASE2","title":"Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2020-05-14","conditions":"COVID19, Hydroxychloroquine, Prophylaxis","enrollment":155},{"nctId":"NCT04349371","phase":"PHASE2","title":"Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-04-21","conditions":"COVID, Coronavirus Infection","enrollment":5},{"nctId":"NCT06739759","phase":"NA","title":"Ovarian Hyperstimulation Syndrome Prevention","status":"RECRUITING","sponsor":"Aljazeera Hospital","startDate":"2024-11-17","conditions":"Ovarian Hyper Stimulation Syndrome (OHSS)","enrollment":300},{"nctId":"NCT04318444","phase":"PHASE2, PHASE3","title":"Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-03-29","conditions":"COVID-19, Corona Virus Infection","enrollment":10},{"nctId":"NCT03428945","phase":"PHASE2","title":"Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2018-08-15","conditions":"Type1 Diabetes Mellitus","enrollment":273},{"nctId":"NCT05471544","phase":"PHASE3","title":"Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan","status":"UNKNOWN","sponsor":"Malaria Consortium","startDate":"2022-07-18","conditions":"Malaria","enrollment":3575},{"nctId":"NCT04755322","phase":"NA","title":"Hydroxychloroquine in Prevention of Preeclampsia","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-03-01","conditions":"Preeclampsia","enrollment":50},{"nctId":"NCT05478954","phase":"PHASE4","title":"Chemoprevention Efficacy Study in Burkina Faso","status":"UNKNOWN","sponsor":"Malaria Consortium","startDate":"2022-07-15","conditions":"Malaria","enrollment":800},{"nctId":"NCT03165136","phase":"PHASE3","title":"Hydroxychloroquine for Prevention of Recurrent Miscarriage.","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2017-12-04","conditions":"Recurrent Miscarriage, First Trimester Abortion","enrollment":300},{"nctId":"NCT05980156","phase":"PHASE4","title":"Comparing Chemoprevention Drugs for School-based Malaria Control","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2023-02-13","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":646},{"nctId":"NCT04331834","phase":"PHASE3","title":"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","status":"COMPLETED","sponsor":"Barcelona Institute for Global Health","startDate":"2020-04-03","conditions":"COVID-19","enrollment":275},{"nctId":"NCT04303507","phase":"NA","title":"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-04-29","conditions":"COVID19, Coronavirus, Acute Respiratory Illnesses","enrollment":4652},{"nctId":"NCT04354870","phase":"PHASE2","title":"COVID-19 PrEP HCW HCQ Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-04-03","conditions":"COVID-19","enrollment":130},{"nctId":"NCT05244954","phase":"PHASE4","title":"Comparing Chemoprevention Approaches for School-based Malaria Control","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2022-02-01","conditions":"Malaria,Falciparum, Anemia in Children","enrollment":746},{"nctId":"NCT01650558","phase":"NA","title":"Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-11","conditions":"HIV","enrollment":1499},{"nctId":"NCT03952650","phase":"PHASE1, PHASE2","title":"Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-05-23","conditions":"Malaria","enrollment":252},{"nctId":"NCT04336748","phase":"PHASE3","title":"HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2020-04","conditions":"Sars-CoV2, Infection Viral, Healthcare Worker","enrollment":""},{"nctId":"NCT04466540","phase":"PHASE4","title":"Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Hospital Alemão Oswaldo Cruz","startDate":"2020-05-12","conditions":"COVID-19","enrollment":1372},{"nctId":"NCT04435808","phase":"PHASE1, PHASE2","title":"Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2020-04-14","conditions":"COVID-19","enrollment":1},{"nctId":"NCT04328961","phase":"PHASE2, PHASE3","title":"Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-03-31","conditions":"COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome)","enrollment":943},{"nctId":"NCT04372017","phase":"PHASE3","title":"Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection","status":"TERMINATED","sponsor":"Sanford Health","startDate":"2020-05-14","conditions":"COVID-19, SARS-CoV 2","enrollment":1},{"nctId":"NCT04590274","phase":"PHASE1","title":"Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","status":"WITHDRAWN","sponsor":"International Brain Research Foundation","startDate":"2020-11","conditions":"Covid19, SARS (Severe Acute Respiratory Syndrome)","enrollment":""},{"nctId":"NCT05110651","phase":"PHASE4","title":"The Danish Pre-HCQ COVID Dialysis Study","status":"WITHDRAWN","sponsor":"Nicholas Carlson","startDate":"2020-04-10","conditions":"COVID-19, End Stage Renal Disease","enrollment":""},{"nctId":"NCT04414241","phase":"PHASE3","title":"Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2020-06-25","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT04381988","phase":"PHASE2","title":"A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-05-07","conditions":"COVID-19, Cancer","enrollment":4},{"nctId":"NCT04354597","phase":"NA","title":"Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients","status":"WITHDRAWN","sponsor":"King Hussein Cancer Center","startDate":"2020-05-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04334148","phase":"PHASE3","title":"Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","status":"COMPLETED","sponsor":"Adrian Hernandez","startDate":"2020-04-22","conditions":"COVID-19","enrollment":1360},{"nctId":"NCT04627467","phase":"PHASE2","title":"Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)","status":"COMPLETED","sponsor":"Fundacion Clinica Valle del Lili","startDate":"2020-03-28","conditions":"Covid19","enrollment":3217},{"nctId":"NCT04330495","phase":"PHASE4","title":"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","status":"WITHDRAWN","sponsor":"Instituto de Investigación Marqués de Valdecilla","startDate":"2020-04-06","conditions":"COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","enrollment":""},{"nctId":"NCT04334928","phase":"PHASE3","title":"Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","status":"COMPLETED","sponsor":"Plan Nacional sobre el Sida (PNS)","startDate":"2020-04-15","conditions":"Coronavirus Infection","enrollment":1002},{"nctId":"NCT01784523","phase":"PHASE3","title":"Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients","status":"TERMINATED","sponsor":"Hospital for Special Surgery, New York","startDate":"2013-02","conditions":"Antiphospholipid Syndrome","enrollment":11},{"nctId":"NCT02874287","phase":"PHASE4","title":"Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2017-10-08","conditions":"Coronary Artery Disease","enrollment":35},{"nctId":"NCT04333225","phase":"PHASE2","title":"Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2020-04-03","conditions":"COVID-19","enrollment":221},{"nctId":"NCT04330144","phase":"PHASE3","title":"Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","status":"WITHDRAWN","sponsor":"Gangnam Severance Hospital","startDate":"2020-04-01","conditions":"Contact Person From COVID-19 Confirmed Patient","enrollment":""},{"nctId":"NCT04342650","phase":"PHASE2","title":"Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2020-04-08","conditions":"COVID-19, SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia","enrollment":152},{"nctId":"NCT04380818","phase":"NA","title":"Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19","status":"UNKNOWN","sponsor":"Grupo de Investigación Clínica en Oncología Radioterapia","startDate":"2020-06-05","conditions":"Pneumonia, Viral","enrollment":106},{"nctId":"NCT04954040","phase":"PHASE2","title":"Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19","status":"UNKNOWN","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2021-02-10","conditions":"Acute Respiratory Distress Syndrome, Covid19","enrollment":132},{"nctId":"NCT04328467","phase":"PHASE3","title":"Pre-exposure Prophylaxis for SARS-Coronavirus-2","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-04-06","conditions":"COVID-19, Corona Virus Infection, ARDS","enrollment":1483},{"nctId":"NCT04340349","phase":"EARLY_PHASE1","title":"Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","status":"UNKNOWN","sponsor":"Instituto Nacional de Rehabilitacion","startDate":"2021-02-01","conditions":"Hydroxychloroquine, Antimalarials, Enzyme Inhibitors","enrollment":214},{"nctId":"NCT04858633","phase":"PHASE3","title":"Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-03-22","conditions":"Covid19, COVID-19 Prevention","enrollment":1000},{"nctId":"NCT03083847","phase":"PHASE1","title":"Dose Escalation PfSPZ-CVac","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"Malaria","enrollment":55},{"nctId":"NCT04308668","phase":"PHASE3","title":"Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-03-17","conditions":"Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection","enrollment":1312},{"nctId":"NCT02564471","phase":"PHASE4","title":"Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2016-11-11","conditions":"Rabies","enrollment":103},{"nctId":"NCT04345653","phase":"PHASE2","title":"Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2020-04-14","conditions":"Covid19","enrollment":48},{"nctId":"NCT04374942","phase":"PHASE3","title":"Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?","status":"TERMINATED","sponsor":"Megan Landes","startDate":"2020-04-30","conditions":"Pre-Exposure Prophylaxis, Coronavirus, SARS-CoV 2","enrollment":13},{"nctId":"NCT04351191","phase":"PHASE4","title":"PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","status":"TERMINATED","sponsor":"Government of Punjab, Specialized Healthcare and Medical Education Department","startDate":"2020-04-15","conditions":"Sars-CoV2, Symptomatic Condition, Covid-19","enrollment":137},{"nctId":"NCT04346667","phase":"PHASE4","title":"Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","status":"TERMINATED","sponsor":"Government of Punjab, Specialized Healthcare and Medical Education Department","startDate":"2020-04-14","conditions":"SARS-CoV-2, Coronavirus Infection, Asymptomatic Condition","enrollment":125},{"nctId":"NCT04788355","phase":"PHASE3","title":"Prevention of Complications (SARS-CoV-2): Clinical Study","status":"COMPLETED","sponsor":"Universidade do Vale do Sapucai","startDate":"2020-07-01","conditions":"Complication","enrollment":176},{"nctId":"NCT04389359","phase":"PHASE2, PHASE3","title":"PROphylaxis for paTiEnts at Risk of COVID-19 infecTion","status":"WITHDRAWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2020-09","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04668469","phase":"NA","title":"Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","status":"COMPLETED","sponsor":"Benha University","startDate":"2020-06-08","conditions":"Covid19","enrollment":600},{"nctId":"NCT04329923","phase":"PHASE2","title":"The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","status":"TERMINATED","sponsor":"Ravi Amaravadi, MD","startDate":"2020-04-09","conditions":"COVID-19","enrollment":173},{"nctId":"NCT04652648","phase":"PHASE4","title":"Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts","status":"COMPLETED","sponsor":"Bryn Mawr Hospital","startDate":"2020-05-27","conditions":"Covid19, Hydroxychloroquine, Coronavirus Infection","enrollment":54},{"nctId":"NCT04364815","phase":"PHASE3","title":"The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial","status":"WITHDRAWN","sponsor":"University of the Philippines","startDate":"2020-12","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04542694","phase":"PHASE3","title":"Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-05-21","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04347889","phase":"PHASE2","title":"Preventing COVID-19 in Healthcare Workers With HCQ: A RCT","status":"WITHDRAWN","sponsor":"Stony Brook University","startDate":"2020-04-20","conditions":"Covid-19","enrollment":""},{"nctId":"NCT04597775","phase":"PHASE2, PHASE3","title":"Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis","status":"UNKNOWN","sponsor":"Regional Center for Disease Control and Prevention, Jordan","startDate":"2020-10-27","conditions":"SARS-CoV Infection","enrollment":93},{"nctId":"NCT04446104","phase":"PHASE3","title":"A Preventive Treatment for Migrant Workers at High-risk of COVID-19","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2020-05-13","conditions":"Covid-19","enrollment":4257},{"nctId":"NCT04384458","phase":"NA","title":"Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis","status":"UNKNOWN","sponsor":"Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara","startDate":"2020-07-20","conditions":"Coronavirus Infections","enrollment":400},{"nctId":"NCT04363450","phase":"PHASE3","title":"Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","status":"UNKNOWN","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2020-04-27","conditions":"COVID-19, Corona Virus Infection, Wuhan Coronavirus","enrollment":1700},{"nctId":"NCT04349228","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals","status":"WITHDRAWN","sponsor":"Abderrahmane Mami Hospital","startDate":"2020-04-28","conditions":"COVID19, Sars-CoV2, Hydroxychloroquine","enrollment":""},{"nctId":"NCT04437693","phase":"PHASE2, PHASE3","title":"Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2020-08-31","conditions":"COVID 19","enrollment":500},{"nctId":"NCT04329611","phase":"PHASE3","title":"ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","status":"TERMINATED","sponsor":"Dr. Michael Hill","startDate":"2020-04-13","conditions":"COVID-19","enrollment":148},{"nctId":"NCT04326725","phase":"","title":"Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia","status":"UNKNOWN","sponsor":"Istinye University","startDate":"2020-03-20","conditions":"Pneumonitis, Coronavirus Infection","enrollment":80},{"nctId":"NCT04438837","phase":"NA","title":"Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers","status":"UNKNOWN","sponsor":"Rambam Health Care Campus","startDate":"2020-07","conditions":"Coronavirus Disease 2019 (COVID-19), Post-Exposure Prophylaxis","enrollment":582},{"nctId":"NCT04434248","phase":"PHASE2, PHASE3","title":"An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Chromis LLC","startDate":"2020-04-23","conditions":"COVID-19","enrollment":330},{"nctId":"NCT02648464","phase":"PHASE4","title":"Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2016-02-01","conditions":"Myocardial Infarction, Acute Coronary Syndrome, Inflammation","enrollment":125},{"nctId":"NCT04347512","phase":"PHASE3","title":"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","status":"WITHDRAWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-06-02","conditions":"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","enrollment":""},{"nctId":"NCT04359537","phase":"PHASE2","title":"Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19","status":"UNKNOWN","sponsor":"Shaheed Zulfiqar Ali Bhutto Medical University","startDate":"2020-05-01","conditions":"COVID 19","enrollment":200},{"nctId":"NCT04377646","phase":"PHASE3","title":"A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers","status":"UNKNOWN","sponsor":"Military Hospital of Tunis","startDate":"2020-05-04","conditions":"Sars-CoV2, COVID19","enrollment":660},{"nctId":"NCT04370015","phase":"NA","title":"Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.","status":"UNKNOWN","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2020-05-15","conditions":"SARS-CoV-2, Healthcare Workers","enrollment":374},{"nctId":"NCT03400254","phase":"PHASE1, PHASE2","title":"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")","status":"WITHDRAWN","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2019-02-26","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT03278808","phase":"PHASE2","title":"Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis","status":"WITHDRAWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2018-09-17","conditions":"Malaria","enrollment":""},{"nctId":"NCT04153201","phase":"NA","title":"Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2013-01-15","conditions":"Antiphospholipid Syndrome","enrollment":50},{"nctId":"NCT04022421","phase":"NA","title":"Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-10-01","conditions":"Behcet's Syndrome, Vascular Type","enrollment":50},{"nctId":"NCT02859350","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2016-11","conditions":"Malaria","enrollment":135},{"nctId":"NCT01845701","phase":"PHASE3","title":"Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2010-03","conditions":"Malaria","enrollment":720},{"nctId":"NCT01376167","phase":"PHASE2","title":"Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-24","conditions":"Malaria, Vivax","enrollment":851},{"nctId":"NCT02511054","phase":"PHASE1","title":"Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-21","conditions":"Malaria","enrollment":57},{"nctId":"NCT02115516","phase":"PHASE1","title":"Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":67},{"nctId":"NCT01728701","phase":"PHASE1","title":"Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2012-09","conditions":"Malaria, Plasmodium Falciparum","enrollment":30},{"nctId":"NCT00132535","phase":"NA","title":"Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2003-08","conditions":"Malaria in Pregnancy, HIV Infections","enrollment":2548},{"nctId":"NCT01443130","phase":"PHASE3","title":"Chloroquine for Malaria in Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-02","conditions":"Malaria","enrollment":900},{"nctId":"NCT02098590","phase":"NA","title":"Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-10","conditions":"Malaria","enrollment":40},{"nctId":"NCT02080026","phase":"NA","title":"Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-06","conditions":"Malaria","enrollment":15},{"nctId":"NCT01103063","phase":"PHASE3","title":"Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Intermittent Preventive Treatment In Pregnancy (IPTp)","enrollment":2891},{"nctId":"NCT01103713","phase":"PHASE3","title":"Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-03","conditions":"Asymptomatic Parasitemia In Pregnancy","enrollment":168},{"nctId":"NCT01783340","phase":"PHASE1, PHASE2","title":"Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis","status":"WITHDRAWN","sponsor":"Radboud University Medical Center","startDate":"2013-04","conditions":"Malaria, Falciparum","enrollment":""},{"nctId":"NCT01236612","phase":"NA","title":"Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2011-04","conditions":"Plasmodium Falciparum Malaria","enrollment":25},{"nctId":"NCT00290420","phase":"PHASE4","title":"Prevention of P. Vivax Malaria During Pregnancy in Bolivia","status":"WITHDRAWN","sponsor":"Institut de Recherche pour le Developpement","startDate":"2006-03","conditions":"Malaria","enrollment":""},{"nctId":"NCT01422954","phase":"NA","title":"Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2012-01","conditions":"Malaria, Plasmodium Falciparum","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":115,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CQ"],"phase":"marketed","status":"active","brandName":"Chloroquine prophylaxis","genericName":"Chloroquine prophylaxis","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chloroquine is a small molecule used as a prophylactic intervention for conditions such as malaria and COVID-19, as indicated by studies registered on ClinicalTrials.gov. Its mechanism of action is not specified in the provided information, but it is classified as a small molecule according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}